Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETAL
2024-517942-33-03Phase 3Authorised
- Sponsor
- Fondazione Toscana Gabriele Monasterio
- Start
- Jan 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of flutemetamol in cardiac amyloidosis, sponsored by Fondazione Toscana Gabriele Monasterio. Planned start Jan 2025; status: authorised.
02
Drugs
flutemetamol
03
Conditions
cardiac amyloidosis
Beyond the preview
Go deeper on 2024-517942-33-03.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517942-33-03.